{"product_id":"brain-drug-delivery-neurological-disorders","title":"Brain Drug Delivery for the Treatment of Neurological Disorders","description":"\u003ch3\u003e\u003cstrong\u003eTouraj Ehtezazi (Editor)\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eISBN:\u003c\/strong\u003e 9781032771915\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublished:\u003c\/strong\u003e August 10, 2026\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e Hardcover\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublisher:\u003c\/strong\u003e CRC Press (Routledge)\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eBrain Drug Delivery for the Treatment of Neurological Disorders, edited by Touraj Ehtezazi (Reader in Pharmaceutics, Liverpool John Moores University), gathers the pharmaceutical science needed to design new treatments for chronic, non-communicable neurological disorders — conditions that, unlike stroke or infectious brain disease, still lack a coordinated research and delivery framework. Fourteen chapters from an international group of contributors cover the blood-brain barrier's role in treatment resistance, physiological barriers to drug delivery, novel nanoparticle and exosome-based delivery systems, monoclonal antibody targeting, and the industrial and regulatory steps required to bring a brain-targeted therapy to market. Part of the established Drugs and the Pharmaceutical Sciences series.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eKey Features\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e- Summarizes in vitro and in vivo evaluation methods for brain drug delivery systems, including techniques that complement imaging approaches such as IVIS.\u003cbr\u003e- Surveys novel delivery platforms in active development, including nanoparticles, exosomes, and monoclonal antibodies engineered to cross the blood-brain barrier. \u003ca href=\"https:\/\/clnzbooks.com\/blogs\/news\/blood-brain-barrier-nanoparticle-delivery-2026\" style=\"color: #8b0000; text-decoration: underline; font-weight: bold;\"\u003eRead our blog post on blood-brain barrier nanoparticle delivery\u003c\/a\u003e.\u003cbr\u003e- Addresses industrial-scale production and the regulatory considerations formulation scientists must plan for before a brain-targeted therapy can reach clinical use.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eCoverage\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e- Physiological barriers that limit drug delivery to the diseased brain, and strategies to overcome them\u003cbr\u003e- Novel nanoparticle and exosome-based delivery systems, and monoclonal antibody targeting of the brain\u003cbr\u003e- Hematological, immunological, and cytotoxic safety evaluation of brain-targeted delivery systems\u003cbr\u003e- Personalised therapies for rare neurological disorders, and industrial and regulatory considerations for scale-up\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eAbout the Editor\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eTouraj Ehtezazi is a Reader in Pharmaceutics at Liverpool John Moores University. He trained as a pharmacist at the University of Tabriz, Iran, earned his PhD from the University of Nottingham in 1997, and held posts at Nottingham and the University of Leicester before joining Liverpool John Moores in 2002, where his research focuses on drug delivery systems for neurological disease.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eTable of Contents\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e1. Neurological Disorders and Their Impact\u003cbr\u003e2. Physiological Barriers of Targeting the Diseased Brain\u003cbr\u003e3. Poly (ADP-Ribose) Polymerase (PARP) as a Novel Therapeutic Target for Developing Treatments Against Neurological and Neurodegenerative Conditions\u003cbr\u003e4. Targeting Microglia for the Treatment of the Diseased Brain\u003cbr\u003e5. Novel Nanoparticles as Drug Delivery Systems to the Brain\u003cbr\u003e6. Exosomes for Drug Delivery to the Brain\u003cbr\u003e7. Targeting the Brain with Monoclonal Antibodies\u003cbr\u003e8. In Vitro Evaluations of Drug Delivery to the Brain\u003cbr\u003e9. In Vivo Evaluations of Drug Delivery to the Brain\u003cbr\u003e10. Introduction to Hematological and Immunological Safety in Brain Drug Delivery\u003cbr\u003e11. Cytotoxic Evaluations of the Drug Delivery Systems to the Brain\u003cbr\u003e12. Personalised Therapies for Rare Neurological Disorders\u003cbr\u003e13. Industrial Aspects to Be Considered for Drug Delivery for Brain\u003cbr\u003e14. Regulatory Aspects to Be Considered in the Development of Drug Delivery Systems to the Brain\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eWhy buy this book?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eNon-communicable neurological disorders are rising in prevalence worldwide, yet the pharmaceutical science needed to get a therapy across the blood-brain barrier remains fragmented across journals and specialties. This volume brings formulation science, in vitro\/in vivo evaluation methods, and the industrial and regulatory pathway together in one reference, making it a practical acquisition for pharmaceutical science departments, neuroscience research libraries, and drug development teams working on CNS-targeted therapies.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/clnzbooks.com\/collections\/medicine\" style=\"color: #8b0000; text-decoration: underline; font-weight: bold;\"\u003eBrowse more titles in our Medicine collection\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eKeywords\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ebrain drug delivery, blood-brain barrier, neurological disorders, nanoparticle drug delivery, exosome drug delivery, monoclonal antibodies brain, CNS pharmaceutics, Touraj Ehtezazi, drugs and the pharmaceutical sciences\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical scientists, pharmacologists, neuroscience researchers, drug delivery formulation scientists, academic and research libraries\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eGenre\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003ePharmacology, Drug Delivery, Neurology\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is this book about?\u003c\/strong\u003e\u003cbr\u003eIt covers the pharmaceutical science behind delivering drugs across the blood-brain barrier to treat chronic neurological disorders, including delivery systems, evaluation methods, and the regulatory pathway to clinical use.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho edited Brain Drug Delivery for the Treatment of Neurological Disorders?\u003c\/strong\u003e\u003cbr\u003eIt was edited by Touraj Ehtezazi, Reader in Pharmaceutics at Liverpool John Moores University, with contributions from an international group of pharmaceutical scientists and clinicians.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDoes the book cover nanoparticle and antibody-based delivery methods?\u003c\/strong\u003e\u003cbr\u003eYes. Separate chapters cover novel nanoparticles, exosomes, and monoclonal antibodies as delivery systems designed to cross the blood-brain barrier. For more context, see our \u003ca href=\"https:\/\/clnzbooks.com\/blogs\/news\/blood-brain-barrier-nanoparticle-delivery-2026\" style=\"color: #8b0000; text-decoration: underline; font-weight: bold;\"\u003eblog post on blood-brain barrier nanoparticle delivery\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIs this book useful for pharmaceutical industry and regulatory teams, not just academics?\u003c\/strong\u003e\u003cbr\u003eYes. Chapters 13 and 14 specifically address industrial-scale production and the regulatory considerations required before a brain-targeted therapy can advance to clinical use.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhere can I buy Brain Drug Delivery for the Treatment of Neurological Disorders?\u003c\/strong\u003e\u003cbr\u003eYou can order Brain Drug Delivery for the Treatment of Neurological Disorders directly from CLNZ Books, with worldwide shipping included and secure payment via credit card or PayPal.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003e📘 Learn more about shipping, delivery times, and returns, see our \u003ca href=\"https:\/\/clnzbooks.com\/pages\/faq-frequently-asked-questions\" style=\"color: #8b0000; text-decoration: underline; font-weight: bold;\"\u003eFAQ here\u003c\/a\u003e\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cstrong\u003e📦 New to ordering with us? See our \u003ca href=\"https:\/\/clnzbooks.com\/pages\/how-to-order\" style=\"color: #8b0000; text-decoration: underline; font-weight: bold;\"\u003eHow to Order\u003c\/a\u003e guide for payment, shipping, and institutional order options.\u003c\/strong\u003e\u003c\/h3\u003e","brand":"CRC Press","offers":[{"title":"Print","offer_id":67780392550474,"sku":"9781032771915","price":446.0,"currency_code":"USD","in_stock":true},{"title":"ebook","offer_id":67780392583242,"sku":"9781003482406","price":396.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0287\/7351\/5338\/files\/BrainDrug_5fddd234-ea13-4aaf-a8bf-0ddcc38cb37d.png?v=1792680570","url":"https:\/\/clnzbooks.com\/products\/brain-drug-delivery-neurological-disorders","provider":"CLNZ Books","version":"1.0","type":"link"}